公开(公告)号：US20210340114A1

公开(公告)日：2021-11-04

申请号：US17226854

申请日：2021-04-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D263/46 ,  A61K31/4418 ,  A61P27/02 ,  A61K31/421 ,  C07D231/22 ,  C07D239/34 ,  A61K31/505 ,  C07D263/38 ,  C07D213/70 ,  C07D213/65 ,  C07D231/12 ,  A61K31/415 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US10544111B2

公开(公告)日：2020-01-28

申请号：US16230634

申请日：2018-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D263/46 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/505 ,  C07D231/12 ,  C07D231/22 ,  C07D239/34 ,  C07D263/38 ,  C07D213/65 ,  A61P27/02 ,  C07D213/70 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20160159808A1

公开(公告)日：2016-06-09

申请号：US14907139

申请日：2014-07-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masanori Kawasaki ,  Satoshi Mikami ,  Shinji Nakamura ,  Nobuyuki Negoro ,  Shuhei Ikeda ,  Izumi Nomura ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Masaki Seto ,  Shigekazu Sasaki ,  Shogo Marui ,  Takahiko Taniguchi

IPC: C07D487/04 ,  C07D498/08 ,  C07D491/08 ,  C07D471/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D473/00 ,  C07D491/08 ,  C07D498/08

Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书所述，或其盐具有PDE2A抑制作用，并且可用作精神分裂症，阿尔茨海默氏病等的预防或治疗药物。

公开(公告)号：US10975043B2

公开(公告)日：2021-04-13

申请号：US16773720

申请日：2020-01-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: A61K31/4418 ,  A61K31/505 ,  C07D239/34 ,  C07D213/65 ,  C07D213/70 ,  C07D263/46 ,  A61K31/415 ,  A61K31/421 ,  C07D231/12 ,  C07D231/22 ,  C07D263/38 ,  A61P27/02 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US10017508B2

公开(公告)日：2018-07-10

申请号：US15264213

申请日：2016-09-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Shinji Nakamura ,  Tomoko Ashizawa ,  Shigekazu Sasaki ,  Takahiko Taniguchi ,  Izumi Nomura ,  Masanori Kawasaki

IPC: C07D241/36 ,  A61K31/498 ,  C07D471/04 ,  C07D519/00 ,  A61K9/20 ,  A61K31/555 ,  C07F7/18

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/498 ,  A61K31/555 ,  C07D519/00 ,  C07F7/1804

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09975903B2

公开(公告)日：2018-05-22

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru Sasaki ,  Fumiaki Kikuchi ,  Zenichi Ikeda ,  Keiko Kakegawa ,  Yoichi Nishikawa ,  Shigekazu Sasaki ,  Koichiro Fukuda ,  Kazuaki Takami ,  Yoshihiro Banno ,  Masahiro Kamaura

IPC: C07D493/04 ,  C07D495/04 ,  C07D321/00 ,  C07D405/06 ,  C07D321/12 ,  C07D413/06 ,  C07D323/00 ,  C07D491/044 ,  C07D313/00 ,  C07D313/20

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].

公开(公告)号：US09556200B2

公开(公告)日：2017-01-31

申请号：US14381347

申请日：2013-03-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomokazu Kusumoto ,  Shigekazu Sasaki ,  Hironobu Maezaki

IPC: A61K31/55 ,  C07D487/06 ,  C07D495/06 ,  C07D491/06

CPC classification number: C07D495/06 ,  C07D487/06 ,  C07D491/06

Abstract: The present invention provides a compound having a superior serotonin 5-HT2C receptor activating action.The present invention relates to a compound represented by the formula (1) wherein ring A is an aromatic carbocycle optionally having substituent(s) or an aromatic heterocycle optionally having substituent(s), X is —N(R1)—, —O— or the like, when ring A is an aromatic carbocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), or the like, and when ring A is an aromatic heterocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), or the like, is a single bond or a double bond, and n is an integer of 0, 1 or 2, or a salt thereof.

Abstract translation: 本发明提供具有优良的5-羟色胺5-HT 2c受体激活作用的化合物。 本发明涉及由式（1）表示的化合物，其中环A是任选具有取代基的芳族碳环或任选具有取代基的芳族杂环，X是-N（R 1） - ， - O - 当环A为任选具有取代基的芳族碳环，则R 1为氢原子，任选具有取代基的烷基等，当环A为任选的芳香族杂环时， 具有取代基，则R 1为氢原子，任选具有取代基的烷基，任选具有取代基的环烷基等为单键或双键，n为 0,1或2的整数，或其盐。

公开(公告)号：US20230295628A1

公开(公告)日：2023-09-21

申请号：US18163506

申请日：2023-02-02

Applicant: National University Corporation Tokyo Medical and Dental University ,  Takeda Pharmaceutical Company Limited

Inventor： Takanori Yokota ,  Tetsuya Nagata ,  Hideki Furukawa ,  Yasuo Nakagawa ,  Takatoshi Yogo ,  Ryosuke Tokunoh ,  Shigekazu Sasaki ,  Kosuke Hidaka ,  Tomohiro Seki ,  Kenichi Miyata ,  Akio Uchida

IPC: C12N15/113 ,  A61P25/00

CPC classification number: C12N15/113 ,  A61P25/00 ,  C12N2310/11 ,  C12N2310/341

Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

公开(公告)号：US11597928B2

公开(公告)日：2023-03-07

申请号：US16980191

申请日：2019-03-13

Applicant: National University Corporation Tokyo Medical and Dental University ,  Takeda Pharmaceutical Company Limited

Inventor： Takanori Yokota ,  Tetsuya Nagata ,  Hideki Furukawa ,  Yasuo Nakagawa ,  Takatoshi Yogo ,  Ryosuke Tokunoh ,  Shigekazu Sasaki ,  Kosuke Hidaka ,  Tomohiro Seki ,  Kenichi Miyata ,  Akio Uchida

IPC: C07H21/04 ,  C12N15/113 ,  A61P25/00

Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent.
Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

公开(公告)号：US20190119225A1

公开(公告)日：2019-04-25

申请号：US16230634

申请日：2018-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D263/46 ,  C07D213/70 ,  A61P27/02 ,  C07D239/34 ,  A61K31/421 ,  C07D213/65 ,  C07D263/38 ,  A61K31/415 ,  C07D231/22 ,  C07D231/12 ,  A61K31/505 ,  A61K31/4418

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.